|Free Dividend Report|
|Stock Splits Calendar|
|ALXN Stock Split History|
|Preferred Stock Newsletter|
|ALXN Options Chain|
|ALXN Message Board|
Alexion Pharmaceuticals (ALXN) has 2 splits in our Alexion Pharmaceuticals stock split history database. The first split for ALXN took place on August 25, 2008. This was a 2 for 1 split, meaning for each share of ALXN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. ALXN's second split took place on May 23, 2011. This was a 2 for 1 split, meaning for each share of ALXN owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as Alexion Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Alexion Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alexion Pharmaceuticals shares, starting with a $10,000 purchase of ALXN, presented on a split-history-adjusted basis factoring in the complete Alexion Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||12.66%|
|About Alexion Pharmaceuticals|
|Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, Co. has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency. According to our Alexion Pharmaceuticals stock split history records, Alexion Pharmaceuticals has had 2 splits.|
|ALXN Split History Table|
|08/25/2008||2 for 1|
|05/23/2011||2 for 1|
|Healthcare Stock Splits|
|ALXN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ALXN shares outstanding history